For the quarter ending 2026-03-31, PLX has $102,336K in assets. $35,107K in debts. $41,001K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 41,001 | 14,680 | 13,647 | 17,895 |
| Short-term bank deposits | 10,082 | 15,593 | 15,723 | 15,503 |
| Restricted deposit | 711 | 702 | - | - |
| Accounts receivable | 2,939 | 8,840 | 14,425 | 9,443 |
| Other assets | 1,149 | 1,129 | 1,452 | 1,513 |
| Inventories | 30,474 | 25,729 | 21,255 | 21,131 |
| Total current assets | 86,356 | 66,673 | 66,502 | 65,485 |
| Funds in respect of employee rights upon retirement | 589 | 578 | 549 | 520 |
| Property and equipment, net | 5,153 | 4,879 | 4,724 | 4,746 |
| Deferred income tax asset | 2,445 | 2,516 | 2,679 | 2,738 |
| Operating lease right of use assets | 7,793 | 7,700 | 7,810 | 4,997 |
| Total assets | 102,336 | 82,346 | 82,264 | 78,486 |
| Trade | 4,285 | 5,259 | 5,375 | 6,689 |
| Other | 21,670 | 19,875 | 15,173 | 15,930 |
| Operating lease liabilities | 1,433 | 1,384 | 1,397 | 1,472 |
| Total current liabilities | 27,388 | 26,518 | 21,945 | 24,091 |
| Liability for employee rights upon retirement | 671 | 661 | 631 | 615 |
| Operating lease liabilities | 7,048 | 6,937 | 6,780 | 3,877 |
| Total long-term liabilities | 7,719 | 7,598 | 7,411 | 4,492 |
| Total liabilities | 35,107 | 34,116 | 29,356 | 28,583 |
| Common stock, 0.001 par value authorized - as of december 31, 2024 and 2025, 185,000,000 shares issued and outstanding - as of december 31, 2024 and 2025, 75,850,275 and 80,425,981 shares, respectively | - | 80 | - | - |
| Additional paid-in capital | - | 433,147 | - | - |
| Accumulated deficit | - | -384,997 | - | - |
| Stockholders' equity | 67,229 | 48,230 | 52,908 | 49,903 |
| Total liabilities and stockholders' equity | 102,336 | 82,346 | 82,264 | 78,486 |
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)